Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. Fundamental Analysis
Santen Pharmaceutical Co., Ltd. (SNPHF) shows moderate financial fundamentals with a PE ratio of 15.45, profit margin of 10.63%, and ROE of 14.41%. The company generates $288.1B in annual revenue with weak year-over-year growth of -0.65%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 65.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze SNPHF's fundamental strength across five key dimensions:
Efficiency Score
WeakSNPHF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentSNPHF trades at attractive valuation levels.
Growth Score
ModerateSNPHF shows steady but slowing expansion.
Financial Health Score
ExcellentSNPHF maintains a strong and stable balance sheet.
Profitability Score
WeakSNPHF struggles to sustain strong margins.
Key Financial Metrics
Is SNPHF Expensive or Cheap?
P/E Ratio
SNPHF trades at 15.45 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, SNPHF's PEG of -0.11 indicates potential undervaluation.
Price to Book
The market values Santen Pharmaceutical Co., Ltd. at 1.67 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 8.11 times EBITDA. This is generally considered low.
How Well Does SNPHF Make Money?
Net Profit Margin
For every $100 in sales, Santen Pharmaceutical Co., Ltd. keeps $10.63 as profit after all expenses.
Operating Margin
Core operations generate 13.22 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $14.41 in profit for every $100 of shareholder equity.
ROA
Santen Pharmaceutical Co., Ltd. generates $7.65 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Santen Pharmaceutical Co., Ltd. produces operating cash flow of $33.73B, showing steady but balanced cash generation.
Free Cash Flow
Santen Pharmaceutical Co., Ltd. generates strong free cash flow of $29.68B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $92.27 in free cash annually.
FCF Yield
SNPHF converts 6.29% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
15.45
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.11
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.67
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.64
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.13
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.68
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.14
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How SNPHF Stacks Against Its Sector Peers
| Metric | SNPHF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 15.45 | 29.28 | Better (Cheaper) |
| ROE | 14.41% | 820.00% | Weak |
| Net Margin | 10.63% | -19731.00% (disorted) | Strong |
| Debt/Equity | 0.13 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 2.68 | 4.69 | Strong Liquidity |
| ROA | 7.65% | -17993.00% (disorted) | Weak |
SNPHF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Santen Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
42.21%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
75.73%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
74.64%
Industry Style: Defensive, Growth, Innovation
High Growth